In brief: Cytopia, Visiomed
Wednesday, 27 April, 2005
Cytopia (ASX:CYT) has received ethics approval to begin a Phase I clinical trial of its anti-cancer drug CYT997 at at the Royal Brisbane and Women's Hospital. The trial will be conducted in association with the Queensland Institute of Medical Research and Q-Pharm. Cytopia chief scientific officer Andrew Wilks said that the 30-patient trial would be a non-blinded, dose escalation study in patients with various cancers and could take between nine and twelve months.
Visiomed has received an initial purchase order for approximately 1500 Funhaler asthma spacers from its Australian distributor, Cottman Australia, a subsidiary of Advance Healthcare Group Limited (ASX:AHG). The order will take up 100 per cent of the Visiomed's first production run.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
